Clinical trials: HiV1- Positive
Human Immunodeficiency Virus 1 Positive, Skin Kaposi Sarcoma
Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection
This phase II clinical trial studies the side effects of pomalidomide and how well it works in treating patients with Kaposi sarcoma and human immunodeficiency virus (HIV) infection.
- Trial name
- NCT03601806
- Testing
- Laboratory Biomarker Analysis, Pomalidomide
- Where
- 3 sites in Kenya, Malawi and 1 more
- Volunteers
- 26 people
- Sponsor
- AIDS Malignancy Consortium
AIDS-Related Kaposi Sarcoma, Human Immunodeficiency Virus 1 Positive
Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
This pilot phase I trial studies how well treatment with vincristine and bleomycin affect quality of life in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma.
- Trial name
- NCT03596918
- Testing
- Bleomycin Sulfate, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- Tanzania
- Volunteers
- 10 people
- Sponsor
- AIDS Malignancy Consortium
Lymphoma, Nonneoplastic Condition
Biomarkers in Blood Samples From Patients With HIV Infection and Stage III or Stage IV Hodgkin Lymphoma Undergoing Chemotherapy
RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment with HIV infection and Hodgkin lymphoma may help doctors learn more about the effects of therapy on HIV.
- Trial name
- NCT01319526
- Testing
- DNA analysis, RNA analysis, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- AIDS Malignancy Consortium
HIV Infections
Computerized Counseling to Promote Positive Prevention and HIV Health in Kenya
The purpose of this study is to see if a computerized counseling tool helps patients reduce their sexual transmission risk and improve their antiretroviral adherence.
- Trial name
- CARE+ Kenya (NCT01015989)
- Testing
- CARE+ Kenya brief computer risk assessment session, CARE+ Kenya computer counseling session
- Where
- 2 sites in Kenya
- Volunteers
- 236 people, healthy volunteers welcome
- Sponsor
- New York University
HIV
Safety and Immunogenicity Study of DNA.HTI, MVA.HTI and ChAdOx1.HTI in HIV-1-positive Patients (AELIX-002)
The AELIX-002 study aims to evaluate the safety and the immunogenicity of an heterologous prime-boost regimen with DNA.HTI, MVA.HTI and ChAdOx1.HTI in early diagnosed and treated HIV-1 positive individuals, males and…
- Trial name
- NCT03204617
- Testing
- DNA.HTI 0.5mL at weeks 0, 4 and 8 + MVA.HTI 0.5mL at weeks 12 and 20 (DDDMM), At least 24 weeks since DDDMM, ChAdOx1.HTI 0.5mL at weeks 0 and 12 + MVA.HTI 0.5mL at week 24 (CCM)
- Where
- Spain
- Volunteers
- 45 people
- Sponsor
- Aelix Therapeutics
Tuberculosis, HIV I Infection
ThiPhiSA: New Pathways to Prevention From Community TB Screening in South Africa
This study will compare community-delivered, multi-month dispensing of tuberculosis preventive therapy (TPT) to standard-of-care clinic-based TPT delivery in a population of South African adults who are recommended to receive TB…
- Trial name
- ThiPhiSA (NCT06214910)
- Testing
- Community-delivered TB preventive therapy (TPT) - 3 months weekly isoniazid plus rifapentine (3HP), Clinic-link TPT
- Where
- South Africa
- Volunteers
- 301 people
- Sponsor
- University of Washington
HIV-1
Impact of Raltegravir on HIV-1 cDNA Slope Following Antiretroviral Therapy (ART) Initiation
Recent clinical trials of combination antiretroviral therapy (cART) containing the first approved integrase inhibitor (i.e. raltegravir) have demonstrated a more rapid decay of HIV-1 RNA in plasma, compared to conventional potent…
- Trial name
- NCT01168167
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Christoph Stephan
Human Immunodeficiency Virus Infection
Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids
More than 150,000 babies became infected with HIV in 2015 alone. When HIV drugs are started before or early in pregnancy, HIV positive women can give birth to HIV negative baby.
- Trial name
- VADICT (NCT03284645)
- Testing
- Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg, Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg, Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily
- Where
- 4 sites in Nigeria
- Volunteers
- 194 people
- Sponsor
- Obafemi Awolowo University
HIV-1-infection, CD4+ T Lymphocytopenia
Pyridostigmine as Immunomodulator in People Living With HIV
Human immunodeficiency virus (HIV) infection is characterized by persistent immune activation and a constant turnover of T cells. This leads to a precipitous fall in the number of T cells, as well as to an early immunosenescence.
- Conditions
- HIV-1-infection, CD4+ T Lymphocytopenia, Immune Deficiency, Immuno-senescence
- Trial name
- NCT03312244
- Testing
- Pyridostigmine Bromide
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
HIV, Peripheral Nervous System Disorders
Safety and Efficacy Study of Prosaptide to Treat Neuropathic Pain in HIV-Positive Patients
This is a double-blind, placebo-controlled, parallel groups study to determine whether prosptide is effective in relieving pain in patients who have sensory neuropathic pain related to their HIV infection or the drugs used to…
- Trial name
- NCT00286377
- Testing
- prosaptide
- Volunteers
- 350 people
- Sponsor
- Savient Pharmaceuticals
HIV Infections, Hemophilia A
Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia
The purpose of this study is to see if indinavir plus two other anti-HIV drugs affect blood clotting in HIV-positive patients with hemophilia.
- Trial name
- NCT00002386
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 8 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Study Evaluating Vaccine in Adults With HIV
The purpose of this study is to learn whether the study vaccine and adjuvants (drugs that are used to help improve immune responses) have an acceptable safety profile in treating individuals with HIV.
- Trial name
- NCT00195234
- Testing
- HIV CTL MEP 1000 micrograms, 19 months per subject
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
HIV Infections
HIV-1 Specific Immune Responses in Thai Individuals With HIV Dementia
A total of 60 participants will be enrolled. They will be in 3 groups 1. ARV-naïve, HIV-positive ≥ 20 year of age with HAD (n=25) who intend to start ARV 2.
- Trial name
- NCT00777426
- Where
- Thailand
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- SEARCH Research Foundation
HIV Infections
An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy
The purpose of this study is to see if it is effective to give HIV positive patients recombinant interleukin-2 (rIL-2) in addition to anti-HIV therapy.
- Trial name
- ESPRIT (NCT00004978)
- Testing
- Recombinant interleukin-2 (rIL-2)
- Where
- 248 sites in United States, Argentina and 23 more
- Volunteers
- 4,150 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals
To find out if it is possible for HIV-1 patients to maintain antiretroviral medications during allogeneic bone marrow transplant
- Trial name
- NCT01836068
- Testing
- Enfuvirtide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HIV -1 Infection, HIV (Human Immunodeficiency Virus)
REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE
Managing HIV well requires taking antiretroviral therapy (ART) every day, but many people living with HIV experience interruptions in their treatment.
- Conditions
- HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
- Trial name
- REINITIATE (NCT07476339)
- Testing
- Bictegravir, emtricitabine, and tenofovir alafenamide
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- CAN Community Health
HIV Infections, Pneumococcal Infections
Safety of and Immune Response to a Pneumococcal Vaccine (PncCV) in HIV Infected and Uninfected Children
Infection by Streptococcal pneumoniae is a common invasive bacterial infection in HIV infected children. The purpose of this study is to determine the safety of and immune response to a pneumococcal polysaccharide-protein…
- Trial name
- NCT00099658
- Testing
- Pneumococcal polysaccharide-protein conjugate vaccine
- Volunteers
- 579 people, healthy volunteers welcome
- Sponsor
- CIPRA SA
HIV Infection, Tuberculosis
Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV
There is a rapidly-growing need to identify evidence-based, safe, and effective co-treatment regimens for HIV-related tuberculosis (TB) among patients who require protease inhibitor (PI)-based antiretroviral therapy (ART).
- Trial name
- NCT01601626
- Testing
- Standard-dose Lopinavir/Ritonavir, Double-dose Lopinavir/Ritonavir, Raltegravir
- Where
- 9 sites in Brazil, Haiti and 3 more
- Volunteers
- 71 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV-1-infection
2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial
The aim of this study is to monitor virological and immunological markers in participants who are switching from a classic triple drug regimen (3DR) to dual therapy (2DR).
- Trial name
- 2DR (NCT04553081)
- Testing
- Dual versus triple therapy in treatment of HIV-1 infection.
- Where
- Belgium
- Volunteers
- 134 people
- Sponsor
- University Hospital, Ghent
Tuberculosis, Human Immunodeficiency Virus Infections
Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment
Protocol Summary Title: Evaluation of safety and efficacy of two different once daily anti-retroviral treatment regimens along with anti-tuberculosis treatment in patients with HIV-1 and tuberculosis - Randomized Controlled…
- Trial name
- NCT00332306
- Testing
- Didanosine, Lamivudine, Efavirenz, Didanosine, Lamivudine, Nevirapine
- Where
- India
- Volunteers
- 180 people
- Sponsor
- Tuberculosis Research Centre, India